Phrontline Biopharma Doses First Patient in Global TJ102 Trial

Phrontline Biopharma, a clinical-stage biotechnology company, has initiated its global Phase I/II study by dosing the first patient with TJ102. This investigational drug is designed as a bispecific, dual-payload antibody-drug conjugate (ADC) for patients with advanced or metastatic ovarian cancer and other solid tumors.

The study, conducted under Investigational New Drug (IND) clearance from the U.S. FDA and Clinical Trial Application approval from China's NMPA, aims to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TJ102. The trial will proceed with dose escalation and expansion cohorts to determine optimal dosages for future development.

TJ102 is built upon Phrontline's proprietary DLP1 linker platform, which enables the conjugation of two distinct payloads to a single antibody molecule. According to the company, this approach allows for dual targeting of FRα and CDH6 antigens, combined with the delivery of two mechanistically different payloads.

CEO Zhaoyuan Chen stated that dosing the first patient marks a significant milestone for the company. Chief Medical Officer Martín Sebastian Olivo added that the trial will rigorously evaluate the drug's safety and early signs of clinical activity, testing the hypothesis that targeting multiple antigens and delivering multiple payloads may overcome resistance seen with current ADC therapies.